Novartis reports data from trial of IgA nephropathy treatment

IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide

Laurus Labs forms JV company

KRKA holds 51% and Laurus Labs holds 49% shareholding

Croda and AAHI partner to drive innovation in vaccine development

The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development

Teva confirms efficacy and safety of Ajovy for prevention of migraine

Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month

Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations

This facility manufactures APIs & formulations of oncology and non-oncology products.

Briefs: Sun Pharma and Kimia Biosciences

Sun Pharma's Dadra facility receives OAI status from US FDA

Merck India appoints Dhananjay Singh as MD Merck Life Science in India

USFDA completes inspection of Lupin's Dabhasa facility with no observations

The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations

Pfizer announces positive results from Phase 3 Study of Abrysvo

ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.

Piramal Pharma forays into men's grooming market in India with the launch of BOHEM